MARLBOROUGH, Mass.,
June 15, 2016 /PRNewswire/
-- Hologic (NASDAQ: HOLX) announced today that the Company
received top marks from U.S. mammography providers in a new
independent report from KLAS Research, with 96 percent of customers
reporting that Hologic systems are worth the
investment.1
In the KLAS report, Tomosynthesis 2016, doctors,
directors of radiology and c-suite executives scored Hologic
highest in overall product satisfaction and confidence that the
company will continue to lead the development of the tomosynthesis
market. The in-depth survey, which was not commissioned by
Hologic, surveyed decision makers at 48 organizations with breast
tomosynthesis systems installed.
"Hologic seems to be the only company that really understands
the tomosynthesis market," a director of radiology told KLAS. "It
was clear from our implementation and our usage of their system
that they are a full generation ahead of other vendors. Everybody
else is playing catch up." Hologic has scored highest in the
mammography market in all five KLAS Tomosynthesis reports.
Provider respondents noted Hologic's high image quality, strong
customer service, and implementation guidance as key reasons for
new system purchases. Additionally, more than 91 percent of
respondents reported a sense of confidence that Hologic's pace of
development will continue to allow for leadership in tomosynthesis
product innovation — a significantly higher score than that of
other manufacturers.
"In the new KLAS Tomosynthesis report, providers conclude once
again that the most-preferred mammogram technology available is
Hologic's Genius™ 3D MAMMOGRAPHY™ exam," said Pete Valenti, Hologic's Division President,
Breast and Skeletal Health Solutions. "Hologic is committed to
leading this market, and we believe there is no company more
dedicated to this industry. The KLAS report shows that mammography
providers are seeing and feeling our strong investment in research
and development, as well as our commitment to customers. We are
committed to developing for our customers the best products that
deliver superior clinical value, patient satisfaction and cost
effectiveness."
The Genius™ 3D MAMMOGRAPHY™ exam is FDA-approved and only
available on the Hologic Selenia® Dimensions®
system. The Genius™ exam is the only mammogram proven to reduce
unnecessary callbacks by up to 40 percent, and detect 41 percent
more invasive cancers than conventional mammography
alone.2,3 Additional information, as well as a locator
to find imaging sites offering Genius™ 3D MAMMOGRAPHY™ exams, can
be found at http://mygenius3d.com/.
About KLAS Research
KLAS is a research and insights firm on a global mission to
improve healthcare delivery by amplifying the provider's voice.
Working with thousands of healthcare professionals and clinicians,
KLAS gathers data and insights on software, services, and medical
equipment to deliver timely reports, trends and statistical
overviews. The research directly represents the provider voice and
acts as a catalyst for improving vendor performance. Follow KLAS on
Twitter at www.twitter.com/KLASresearch.
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With
a unified suite of technologies and a robust research and
development program, Hologic is dedicated to The Science of Sure.
For more information on Hologic, visit www.hologic.com.
Hologic, The Science of Sure, 3D Mammography, Dimensions,
Genius, and Selenia are trademarks and/or registered trademarks of
Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based
Media Contact:
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact
Michael
Watts
858.410.8588
michael.watts@hologic.com
1 "Tomosynthesis 2016. Performance Report." ©
2016 KLAS Enterprises, LLC. All rights reserved.
www.KLASresearch.com
2 Friedewald SM, Rafferty EA, Rose SL, et al. Breast
cancer screening using tomosynthesis in combination with digital
mammography. JAMA. 2014;311(24):2499-2507.
3 Rose SL, Tidwell AL, Bujnoch LJ, et al. Implementation
of breast tomosynthesis in a routine screening practice: an
observational study. AJR Am J Roentgenol.
2013;200(6):1401-1408.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/klas-report-shows-hologic-continuing-to-lead-the-us-breast-tomosynthesis-market-with-genius-3d-mammography-exams-300284748.html
SOURCE Hologic, Inc.